Drug Trial Radar · NCT07038551
Prophylactic Use of Naldemedine on Opioid-induced Nausea and Vomiting in Patients With Cancer: POSEIDON Study
Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Jun 20, 2025
Primary completion
Feb 13, 2026
Study completion Feb 13, 2026
Sponsor
- Lead sponsor
- International University of Health and WelfareAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shionogi
- First posted
- Jun 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Opioid analgesics can cause side effects such as constipation, nausea, and vomiting by acting on opioid receptors widely distributed in the peripheral nervous system. This can sometimes make it difficult to achieve and maintain pain relief and continue pain treatment. Among these side effects, nausea and vomiting are specifically referred to as opioid-induced nausea and vomiting (OINV). OINV is known to occur during the initial administration or dose escalation of opioid analgesics, and it not only decreases the quality of life for patients but also reduces adherence to opioid analgesics, which can have a negative impact on pain management. Therefore, appropriate management is crucial. While the administration of conventional antiemetic drugs is recommended for the treatment of OINV, there is a lack of high-quality studies evaluating their effectiveness, and studies comparing treatment effects with a placebo have not been reported. The objective is to verify the effectiveness of naldemedine in preventing OINV in patients starting opioid analgesics for cancer
Conditions
- Opioid-Induced Nausea and Vomitting(OINV)
Interventions
NaldemedineDrug
over-encapsulated capsule of either 0.2 mg of naldemedine
PlaceboDrug
over-encapsulated capsule of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of patients who achieved a Complete Response on Day 5 (CR5), defined as no vomiting up to 120 hours after starting opioid analgesic and no use of rescue antiemetic medications.Time frame: 120 hours
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Toyohashi municipal hospital
Toyohashi, Aichi-ken, Japan
IUHW Narita Hospital
Narita, Chiba, Japan
Iizuka Hospital
Iizuka, Fukuoka, Japan
Hiroshima Prefectural Hospital
Hiroshima, Hiroshima, Japan
Kansai Rosai Hospital
Amagasaki, Hyōgo, Japan
National Hospital Organization HIMEJI M edical Center
Himeji, Hyōgo, Japan
Hyogo Prefectural Nishinomiya Hospital
Nishinomiya, Hyōgo, Japan
University of Tsukuba Hospital
Tsukuba, Ibaragi, Japan
St. Marianna University School of Medicine
Kawasaki, Kanagawa, Japan
Kanagawa Dental University Yokohama Clinic
Yokohama, Kanagawa, Japan
Kyoto University Hospital
Kyoto, Kyoto, Japan
Osaki Citizen Hospital
Ōsaki, Miyagi, Japan
Kindai University Nara Hospital
Ikoma, Nara, Japan
Niigata Cancer Center Hospital
Niigata, Niigata, Japan
Beppu Medical Center
Beppu, Oita Prefecture, Japan
Osaka Red Cross Hospital
Osaka, Osaka, Japan
National Cancer Center Hospital
Chuo Ku, Tokyo, Japan
Cancer Institute Hospital of Japanese Fo undation for Cancer Research
Tokyo, Tokyo, Japan
Showa University Koto Toyosu Hospital
Tokyo, Tokyo, Japan
Toyama University Hospital
Toyama, Toyama, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.